Shots:
- Zydus has received the US FDA’s approval to initiate clinical trials of Desidustat in CIA. The company has initiated two P-III studies of desidustat
- The P-III DREAM-ND (NCT04012957) study is being conducted in 588 CKD patients not-on-dialysis while the P-III DREAM-D is being conducted in 392 CKD patients on dialysis (NCT04215120)
- The therapy met its 1EPs in P-II study and demonstrated a good safety profile while P-I trials were earlier completed in Australia. Desidustat (PO) is a novel hypoxia-inducible factor prolyl hydroxylase inhibitor, currently undergoing P-III development for anemia in CKD patients, and P-II(b) studies for management of COVID-19 patients
Click here to read full press release/ article | Ref: Zydus | Image: Twitter
